Marcaine Spinal 0,5% Heavy

Bupivacaine Hydrochloride, the active ingredient in Marcaine Spinal 0,5% Heavy, is a local anesthetic presented as a 0.5% (5 mg/mL) injectable solution for intrathecal use. It provides surgical and spinal anesthesia and pain management during operative procedures.

GNH USA supplies Marcaine Spinal 0,5% Heavy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide, ensuring EU‑standard quality and global logistics support.

Marcaine Spinal 0,5% Heavy (bupivacaine hydrochloride) is used for spinal anesthesia in surgical settings. - Surgical anesthesia: provides dense sensory and motor block for procedures requiring complete anesthesia. - Spinal anesthesia: enables regional block for lower abdominal, pelvic, or lower‑limb surgeries. - Pain management during surgery: offers prolonged analgesia throughout the operative period. - Obstetric procedures: facilitates anesthesia for cesarean sections when a spinal technique is chosen.

Marcaine Spinal 0,5% Heavy may cause a range of adverse reactions.

Common Side Effects: - Hypotension: drop in blood pressure after intrathecal injection. - Bradycardia: slowed heart rate, especially in high spinal blocks. - Nausea and vomiting: gastrointestinal upset following anesthesia. - Pruritus: itching, often related to opioid co‑administration. - Urinary retention: difficulty voiding after the block. - Headache: post‑dural puncture headache in some patients.

Serious or Rare Side Effects: - Cardiac arrest: severe cardiotoxicity with high plasma levels. - Ventricular arrhythmias: life‑threatening rhythm disturbances. - Respiratory depression: inadequate ventilation requiring support. - Seizures: central nervous system toxicity at excessive doses. - Allergic reactions: rash, bronchospasm, or anaphylaxis. - Epidural or spinal hematoma: bleeding causing neurologic compromise.

Before using Marcaine Spinal 0,5% Heavy, clinicians should consider several safety measures. - Patient assessment: evaluate cardiovascular status and baseline blood pressure. - Dose limitation: avoid excessive intrathecal volume to reduce toxicity risk. - Allergy check: confirm no hypersensitivity to amide‑type local anesthetics. - Concurrent CNS depressants: use with caution when combined with other sedatives. - Monitoring: observe blood pressure, heart rate, and respiratory function during and after injection. - Store at ambient temperature: keep in original container, protect from light and moisture.

Marcaine Spinal 0,5% Heavy can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Class I antiarrhythmic agents (e.g., quinidine, procainamide): may enhance cardiotoxicity. - Beta‑blockers: increase risk of bradycardia and hypotension. - General anesthetics (e.g., propofol, volatile agents): may potentiate central nervous system depression.

Moderate Interactions (Monitor Closely): - Opioids: additive effect on respiratory depression. - Sedatives (benzodiazepines): may increase sedation and delay recovery. - Magnesium sulfate: can potentiate neuromuscular blockade and affect cardiac conduction.